Two Sigma Investments LP Takes Position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Two Sigma Investments LP bought a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 200,797 shares of the company's stock, valued at approximately $66,000. Two Sigma Investments LP owned about 10.74% of Tonix Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TNXP. Point72 Asset Management L.P. bought a new stake in shares of Tonix Pharmaceuticals in the 4th quarter valued at $526,000. Jane Street Group LLC boosted its position in Tonix Pharmaceuticals by 5,932.3% during the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company's stock valued at $548,000 after acquiring an additional 1,635,119 shares during the last quarter. Northern Trust Corp acquired a new stake in Tonix Pharmaceuticals during the 4th quarter worth about $162,000. Geode Capital Management LLC raised its position in shares of Tonix Pharmaceuticals by 1,600.1% in the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company's stock worth $650,000 after acquiring an additional 1,855,907 shares in the last quarter. Finally, Commonwealth Equity Services LLC bought a new position in shares of Tonix Pharmaceuticals in the 4th quarter worth about $40,000. 82.26% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Tonix Pharmaceuticals

In other Tonix Pharmaceuticals news, CEO Seth Lederman acquired 4,000 shares of the company's stock in a transaction on Thursday, May 15th. The shares were purchased at an average cost of $21.55 per share, with a total value of $86,200.00. Following the completion of the purchase, the chief executive officer now owns 4,005 shares of the company's stock, valued at approximately $86,307.75. This represents a 80,000.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.03% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on TNXP shares. Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Alliance Global Partners restated a "buy" rating on shares of Tonix Pharmaceuticals in a report on Tuesday, June 3rd. Finally, Noble Financial reiterated an "outperform" rating and issued a $70.00 price objective on shares of Tonix Pharmaceuticals in a research note on Thursday, March 20th.

Tonix Pharmaceuticals Price Performance

Shares of TNXP stock traded down $2.05 on Tuesday, reaching $34.92. 412,645 shares of the company were exchanged, compared to its average volume of 926,797. Tonix Pharmaceuticals Holding Corp. has a one year low of $6.76 and a one year high of $137.25. The company has a market cap of $257.01 million, a price-to-earnings ratio of -0.02 and a beta of 2.09. The company has a 50-day moving average of $25.76 and a 200-day moving average of $23.86.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($2.84) EPS for the quarter, beating analysts' consensus estimates of ($3.23) by $0.39. Tonix Pharmaceuticals had a negative return on equity of 120.96% and a negative net margin of 1,313.87%. The firm had revenue of $2.43 million during the quarter, compared to analysts' expectations of $2.55 million. As a group, sell-side analysts predict that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.